Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug 20;4(12):e1052933.
doi: 10.1080/2162402X.2015.1052933. eCollection 2015 Dec.

Retargeted oncolytic viruses provoke tumor-directed T-cell responses

Arnold Kloos  1 , Norman Woller  2 , Rita Gerardy-Schahn  3 , Florian Kühnel  2
Affiliations

Retargeted oncolytic viruses provoke tumor-directed T-cell responses

Arnold Kloos et al. Oncoimmunology. .

Abstract

Intratumoral application of oncolytic viruses effectively induce tumor-directed immune responses. However, their systemic application is typically insufficient to stimulate the required extent of tumor tissue inflammation to elicit antitumor immunity. We recently discovered evidence that this barrier can be overcome by effective molecular retargeting of viral infection.

Keywords: oncolytic virus, molecular retargeting, neoepitope-specific T cell responses.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Molecular retargeting of oncolytic virus to provoke antitumor T-cell responses. Tumor therapy by systemic delivery of oncolytic virus is usually ineffective. In contrast, systemic application of adenovirus, retargeted to tumor cells using a polysialic acid-specific adapter, facilitates effective tumor inflammation subsequently leading to potent tumor-directed CD8+ T-cell responses.
See this image and copyright information in PMC

References

    1. Prestwich RJ, Errington F, Diaz RM, Pandha HS, Harrington KJ, Melcher AA, Vile RG. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther 2009; 20:1119-32; PMID:19630549; http://dx.doi.org/10.1089/hum.2009.135 - DOI - PMC - PubMed
    1. Breitbach CJ, Arulanandam R, De SN, Thorne SH, Patt R, Daneshmand M, Moon A, Ilkow C, Burke J, Hwang TH, et al.. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res 2013; 73:1265-75; PMID:23393196; http://dx.doi.org/10.1158/0008-5472.CAN-12-2687 - DOI - PubMed
    1. Woller N, Knocke S, Mundt B, Gurlevik E, Struver N, Kloos A, Boozari B, Schache P, Manns MP, Malek NP, et al.. Virus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice. J Clin Invest 2011; 121:2570-82; PMID:21646722; http://dx.doi.org/10.1172/JCI45585 - DOI - PMC - PubMed
    1. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015; PMID:26014293; [Epub ahead of print]17545616 - PubMed
    1. Li HJ, Everts M, Pereboeva L, Komarova S, Idan A, Curiel DT, Herschman HR. Adenovirus tumor targeting and hepatic untargeting by a coxsackie/adenovirus receptor ectodomain anti-carcinoembryonic antigen bispecific adapter. Cancer Res 2007; 67:5354-61; PMID:17545616; http://dx.doi.org/10.1158/0008-5472.CAN-06-4679 - DOI - PubMed

LinkOut - more resources